| Hospitalised (n=81) | Non hospitalised (n=55) |
Responders†, n (%) | 67 (82.7) | 45 (81.8) |
Patients stopping OCS, n (%) | 40 (49.4) | 26 (47.3) |
Total OCS burden (g) | | |
Mean change | -1.81* | -1.96* |
12 months pre-→12 months post-omalizumab | 5.77→3.96 (-31.4%) | 5.08→3.12 (-38.6%) |
Exacerbations | | |
Mean change | -1.56* | -2.51* |
12 months pre-→12 months post-omalizumab | 3.4→1.84 (-45.9%) | 4.07→1.56 (-61.7%) |
AQLQ scores at 16 weeks | | |
Mean change | +2.03* | +1.87* |
Baseline→Week 16 | 3.11→5.13 (+65.3%)a | 2.91→4.78 (+64.3%)b |